Chimeric Antigen Receptor T Cell–Mediated Neurotoxicity in Nonhuman Primates
- 31 May 2018
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 8 (6) , 750-763
Abstract
Chimeric antigen receptor (CAR) T-cell immunotherapy has revolutionized the treatment of refractory leukemias and lymphomas, but is associated with significant toxicities, namely cytokine release syndrome (CRS) and neurotoxicity. A major barrier to developing therapeutics to prevent CAR T cell–mediated neurotoxicity is the lack of clinically relevant models. Accordingly, we developed a rhesus macaque (RM) model of neurotoxicity via adoptive transfer of autologous CD20-specific CAR T cells. Following cyclophosphamide lymphodepletion, CD20 CAR T cells expand to 272 to 4,450 cells/μL after 7 to 8 days and elicit CRS and neurotoxicity. Toxicities are associated with elevated serum IL6, IL8, IL1RA, MIG, and I-TAC levels, and disproportionately high cerebrospinal fluid (CSF) IL6, IL2, GM-CSF, and VEGF levels. During neurotoxicity, both CD20 CAR and non-CAR T cells accumulate in the CSF and in the brain parenchyma. This RM model demonstrates that CAR T cell–mediated neurotoxicity is associated with proinflammatory CSF cytokines and a pan–T cell encephalitis. Significance: We provide the first immunologically relevant, nonhuman primate model of B cell–directed CAR T-cell therapy–mediated CRS and neurotoxicity. We demonstrate CAR and non-CAR T-cell infiltration in the CSF and in the brain during neurotoxicity resulting in pan-encephalitis, accompanied by increased levels of proinflammatory cytokines in the CSF. Cancer Discov; 8(6); 750–63. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 663Keywords
All Related Versions
Funding Information
- HHS | NIH | National Cancer Institute (NCI) (P01CA065493)
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases (DIR, NIAID) (1UM1AI126617)
- HHS | NIH | National Institute of Child Health and Human Development (NICHD) (U19AI117945)
- HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) (R33AI116184)
- HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) (1R01HL095791)
- St. Baldrick's Foundation
- Conquer Cancer Foundation (CCF)
- ASBMT
- HHS | NIH | National Institute of Child Health and Human Development (NICHD) (2U19AI051731)
- NIH Ruth L. Kirschstein NRSA Training Grant (T32CA009351)
- HHS | NIH | National Cancer Institute (NCI) (R01CA136551)
- University of Washington Cancer Consortium/CCSG (P30CA015704)
This publication has 41 references indexed in Scilit:
- Cytokine‐mediated blood brain barrier disruption as a conduit for cancer/chemotherapy‐associated neurotoxicity and cognitive dysfunctionInternational Journal of Cancer, 2016
- Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivoLeukemia, 2015
- Structural and functional features of central nervous system lymphatic vesselsNature, 2015
- Chimeric Antigen Receptors With Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor EfficacyMolecular Therapy, 2015
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialThe Lancet, 2015
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyThe Lancet Oncology, 2015
- TRIM5α Variations Influence Transduction Efficiency With Lentiviral Vectors in Both Human and Rhesus CD34+ Cells In Vitro and In VivoMolecular Therapy, 2014
- High-efficiency Transduction of Rhesus Hematopoietic Repopulating Cells by a Modified HIV1-based Lentiviral VectorMolecular Therapy, 2012
- Interleukin‐6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosusArthritis & Rheumatism, 2007
- Molecular mechanisms involved in T cell migration across the blood–brain barrierJournal of Neural Transmission, 2006